25 November 2017
News and Views
Links and Services
A study in this week's issue of the New England Journal of Medicine investigates rifaximin therapy for patients with irritable bowel syndrome without constipation.
Evidence suggests that gut flora may play an important role in the pathophysiology of the irritab
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors